DUBLIN – Numab Therapeutics AG is banking an equity investment of CHF15 million (US$15.2 million) from its latest Asian partner, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd., as part of a broad alliance to develop up to five multispecific antibodies from three programs based on Numab’s Match platform.

HONG KONG – Singapore and U.S.-based Hummingbird Bioscience Pte Ltd. has raised $19 million in a series B financing round. Proceeds will be used to support the discovery of new disease targets and to fuel the work of co-discovery projects that are part of a multitarget collaboration agreement valued at more than $1 billion signed with Amgen Inc. in September.